Public Joint-Stock Company "Human Stem Cells Institute" reported earnings results for the full year ended December 31, 2022. For the full year, the company reported revenue was RUB 1,136.9 million compared to RUB 1,180.79 million a year ago. Net income was RUB 46.12 million compared to RUB 11.63 million a year ago.

Basic earnings per share from continuing operations was RUB 0.53 compared to RUB 0.15 a year ago. Diluted earnings per share from continuing operations was RUB 0.53 compared to RUB 0.15 a year ago.